Industries de la santé
New data confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity (NEDA)’ based on four key measures of MS
			
					
						
				
			
					
						
				
			
						
		| 16 Septembre 2014
A key treatment goal for patients with MS is ‘no evidence of disease activity’ (NEDA), currently defined as no relapses, MRI lesions and disability progressionIncluding MS-related brain shrinkage (brain volume loss) as a fourth key measure captures underlying damage that begins early in MS and is associated with loss of function
The likelihood of achieving NEDA across four key...






